Articles By Estel Grace Masangkay

  1. Pharma Industry Sales To Hit $1 Trillion In 2014, Says CMR Report 9/12/2014

    A new upcoming report from Thomson Reuters unit CMR International declares that several positive trends are buoying the pharmaceutical industry to an all-time high in sales, which are projected to hit $1 trillion this year.

  2. Relypsa Chooses Patheon As Supply Partner For Patiromer 9/11/2014

    Biopharmaceutical firm Relypsa announced that it has entered into a multi-year agreement with Patheon for the finished product manufacture and supply of patiromer.

  3. EC Approves Lilly And BI's Insulin Glargine Product 9/11/2014

    Eli Lilly & Co. together with its partner Boehringer Ingelheim announced that the European Commission (EC) has granted marketing authorization to the companies’ insulin glargine product for diabetes in the EU. The product is the first biosimilar insulin to be approved through the European Medicines Agency's (EMA) biosimilar pathway.

  4. Cipla Links With S&D Pharma For Fullhale Launch In EU 9/11/2014

    Cipla, an India-based generic pharma firm, announced its collaboration with U.K.-based S&D Pharma for the marketing of Cipla’s products in the Czech Republic and Slovakia.

  5. FDA OKs Astute Medical's Acute Kidney Injury Assay 9/9/2014

    The U.S. Food and Drug Administration (FDA) announced that it has authorized the marketing of Astute Medical’s Astute NephroCheck test, a first-of-a-kind lab assay to determine whether a patient is at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the test.

  6. Roche's RoACTEMRA EU Label Update Approved 9/9/2014

    Roche reported that its label expansion to its rheumatoid arthritis (RA) drug RoACTEMRA (tocilizumab) has been approved in the EU.

  7. NICE Recommends Alexion's Eculizumab For aHUS 9/8/2014

    Alexion Pharmaceuticals announced that it has received positive recommendation from the National Institute for Health and Clinical Excellence (NICE) for its drug eculizumab as treatment for the rare disease atypical hemolytic uremic syndrome (aHUS) in the U.K.

  8. J&J Fast Tracks Ebola Vaccine, Will Start Trials In 2015 9/8/2014

    Johnson & Johnson announced that it has decided to fast track its Ebola vaccine development program in partnership with the U.S. National Institutes of Health (NIH) and the Denmark-based biotech Bavarian Nordic.

  9. Bayer Files For New Eylea Indication In Japan 9/8/2014

    Bayer announced that its unit Bayer Yakuhin has filed a new Marketing Authorization application in Japan for aflibercept solution for injection into the eye as treatment for branch retinal vein occlusion (BRVO).

  10. EMA Grants 2 Orphan Designations To Cerenis' CER-001 9/5/2014

    Biopharmaceutical company, Cerenis Therapeutics, announced that it has received two separate Orphan Drug designations from the European Medicines Agency (EMA) for its drug CER-001 for the treatment of cardiovascular disease.